Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 20, 2019

View Archived Issues

IP-1867B ablates EGFR inhibitor resistance in adult high-grade gliomas

First-in-human results for the chlamydia vaccine candidate CTH-522

RNA-binding protein 39 degradation inducers patented by the Dana-Farber Cancer Institute

Bristol-Myers Squibb discovers receptor-interacting serine/threonine-protein kinase 1 inhibitors

LDD-1819 has cell reprograming and dual kinase inhibitory activity

New chemical entities designed by DINGOS machine learning model

Phase II biomarker study of oral dexpramipexole in moderate to severe eosinophilic asthma

Positive recommendation to continue enrollment in phase Ib study of OTS Allocetra

Vanda receives complete response letter regarding sNDA for Hetlioz for treatment of jet lag disorder

Preclinical data presented for the novel re-engineered lupus autoantibody PAT-DX1

SU-011 improves glycemic control in vivo without the risk of hypoglycemia and weight gain

Exelixis discovers AXL/Mer/c-Met inhibitors

RAPT Therapeutics describes new C-C chemokine receptor type 4 antagonists

PD-1/PD-L1 interaction inhibitors patented by Bristol-Myers Squibb

Sarepta Therapeutics receives complete response letter for golodirsen

Cephamycins treat spore-forming bacteria, prevent relapses

FDA approves Xenleta for the treatment of community-acquired bacteria pneumonia

Oxurion reports topline results from phase IIa study of THR-317 plus ranibizumab in DME

Farxiga meets primary endpoint in landmark phase III DAPA-HF study

First patient enrolled in phase IIb study of ABX-464 in patients with ulcerative colitis

Forendo Pharma initiates dosing in phase Ib study of FOR-6219

What wakes up CMV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
EASL spotlight: TUNE-401 advances epigenetic silencing in HBV
BioWorld
Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...